Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs

Vaccine

Volumn 32, Issue 15, 2014, Pages 1716-1719

  McGettigan, James P ^a,b   David, Frederic ^c   Figueiredo, Monica Dias ^c   Minke, Jules ^d   Mebatsion, Teshome ^c   Schnell, Matthias J ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Merial ^*  (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Canine; Rabies; Replication deficient RABV; Vaccine

Indexed keywords

RABIES VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; EXPERIMENTAL DOG; FEMALE; GENE DELETION; IMMUNOGENICITY; MALE; MASS IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RABIES; SEROLOGY; SINGLE DRUG DOSE; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN;

CANINE; RABIES; REPLICATION-DEFICIENT RABV; VACCINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOG DISEASES; DOGS; FEMALE; GENE DELETION; MALE; RABIES; RABIES VACCINES; RABIES VIRUS; VIRAL MATRIX PROTEINS;

EID: 84895883997     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.043     Document Type: Article

References (32)

1. Belotto A., Leanes L.F., Schneider M.C., Tamayo H., Correa E. Overview of rabies in the Americas. Virus Res 2005, 111:5-12.
2. Lembo T., Hampson K., Kaare M.T., Ernest E., Knobel D., Kazwala R.R., Haydon D.T., Cleaveland S. The feasibility of canine rabies elimination in Africa: dispelling doubts with data. PLoS Negl Trop Dis 2010, 4:e626.
3. Coetzee P., Nel L.H. Emerging epidemic dog rabies in coastal South Africa: a molecular epidemiological analysis. Virus Res 2007, 126:186-195.
4. CDC, 2012 http://www.cdc.gov/rabies/location/usa/cost.html.
5. Hu R.L., Fooks A.R., Zhang S.F., Liu Y., Zhang F. Inferior rabies vaccine quality and low immunization coverage in dogs (Canis familiaris) in China. Epidemiol Infect 2008, 136:1556-1563.
6. Davlin S.L., Vonville H.M. Canine rabies vaccination and domestic dog population characteristics in the developing world: a systematic review. Vaccine 2012, 30:3492-3502.
7. Durr S., Meltzer M.I., Mindekem R., Zinsstag J. Owner valuation of rabies vaccination of dogs, Chad. Emerg Infect Dis 2008, 14:1650-1652.
8. Cenna J., Hunter M., Tan G.S., Papaneri A.B., Ribka E.P., Schnell M.J., Marx P.A., McGettigan J.P. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis 2009, 200:1251-1260.
9. Dorfmeier C.L., Lytle A.G., Dunkel A.L., Gatt A., McGettigan J.P. Protective vaccine-induced CD4+ T cell-independent B cell responses against rabies infection. J Virol 2012.
10. Dorfmeier C.L., Shen S., Tzvetkov E.P., McGettigan J.P. Reinvestigating the role of IgM in rabies virus post-exposure vaccination. J Virol 2013.
11. Mebatsion T., Weiland F., Conzelmann K.K. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J Virol 1999, 73:242-250.
12. Dorfmeier C.L., Lytle A.G., Dunkel A.L., Gatt A., McGettigan J.P. Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection. J Virol 2012, 86:11533-11540.
13. Dorfmeier C.L., Tzvetkov E.P., Gatt A., McGettigan J.P. Investigating the role for IL-21 in rabies virus vaccine-induced immunity. PLoS Negl Trop Dis 2013, 7:e2129.
14. Cenna J., Tan G.S., Papaneri A.B., Dietzschold B., Schnell M.J., McGettigan J.P. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 2008, 26:6405-6414.
15. Briggs D.J., Schweitzer K. Importation of dogs and cats to rabies-free areas of the world. Vet Clin N Am Small Anim Pract 2001, 31:573-583. viii.
16. Moore S.M., Hanlon C.A. Rabies-specific antibodies: measuring surrogates of protection against a fatal disease. PLoS Negl Trop Dis 2010, 4:e595.
17. Fooks A.R., McElhinney L.M., Brookes S.M., Johnson N., Keene V., Parsons G., Soldan A. Rabies antibody testing and the UK pet travel scheme. Vet Rec 2002, 150:428-430.
18. Berndtsson L.T., Nyman A.K., Rivera E., Klingeborn B. Factors associated with the success of rabies vaccination of dogs in Sweden. Acta Vet Scand 2011, 53. 22-0147-53-22.
19. Mansfield K.L., Burr P.D., Snodgrass D.R., Sayers R., Fooks A.R. Factors affecting the serological response of dogs and cats to rabies vaccination. Vet Rec 2004, 154:423-426.
20. Gazi A., Seyyal A. Detection of neutralising antibody titration in vaccinated owned and Stray dogs against rabies virus. J Fac Vet Med Istanbul Univ 2011, 37:97.
21. Cliquet F., Verdier Y., Sagne L., Aubert M., Schereffer J.L., Selve M., Wasniewski M., Servat A. Neutralising antibody titration in 25,000 sera of dogs and cats vaccinated against rabies in France, in the framework of the new regulations that offer an alternative to quarantine. Rev Sci Tech 2003, 22:857-866.
22. Watanabe I., Yamada K., Aso A., Suda O., Matsumoto T., Yahiro T., Ahmed K., Nishizono A. Relationship between virus-neutralizing antibody levels and the number of rabies vaccinations: a prospective study of dogs in Japan. Jpn J Infect Dis 2013, 66:17-21.
23. Minke J.M., Bouvet J., Cliquet F., Wasniewski M., Guiot A.L., Lemaitre L., Cariou C., Cozette V., Vergne L., Guigal P.M. Comparison of antibody responses after vaccination with two inactivated rabies vaccines. Vet Microbiol 2009, 133:283-286.
24. Osorio J.E., Tomlinson C.C., Frank R.S., Haanes E.J., Rushlow K., Haynes J.R., Stinchcomb D.T. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine 1999, 17:1109-1116.
25. Lodmell D.L., Ewalt L.C., Parnell M.J., Rupprecht C.E., Hanlon C.A. One-time intradermal DNA vaccination in ear pinnae one year prior to infection protects dogs against rabies virus. Vaccine 2006, 24:412-416.
26. Tims T., Briggs D.J., Davis R.D., Moore S.M., Xiang Z., Ertl H.C., Fu Z.F. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine 2000, 18:2804-2807.
27. Zhang S., Liu Y., Fooks A.R., Zhang F., Hu R. Oral vaccination of dogs (Canis familiaris) with baits containing the recombinant rabies-canine adenovirus type-2 vaccine confers long-lasting immunity against rabies. Vaccine 2008, 26:345-350.
28. Yuan Z., Zhang S., Liu Y., Zhang F., Fooks A.R., Li Q., Hu R. A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs. Vaccine 2008, 26:1314-1321.
29. Amann R., Rohde J., Wulle U., Conlee D., Raue R., Martinon O., Rziha H.J. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. J Virol 2013, 87:1618-1630.
30. Hu R., Zhang S., Fooks A.R., Yuan H., Liu Y., Li H., Tu C., Xia X., Xiao Y. Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes Infect 2006, 8:1090-1097.
31. Ertl H.C. Novel vaccines to human rabies. PLoS Negl Trop Dis 2009, 3:e515.
32. Wright N., Jackson F.R., Niezgoda M., Ellison J.A., Rupprecht C.E., Nel L.H. High prevalence of antibodies against canine adenovirus (CAV) type 2 in domestic dog populations in South Africa precludes the use of CAV-based recombinant rabies vaccines. Vaccine 2013.